Latest Global Growth News

AFT Pharmaceuticals reports a robust 33% revenue increase in the first half of FY26, driven by strong ANZ market performance and expanding international presence. The company advances its R&D pipeline and targets NZ$300 million revenue for FY27 amid strategic global expansion.

Airtasker Limited has announced a $10 million equity capital raise to accelerate marketing efforts in the UK and US, following a strong first quarter with group revenue up 20.5% year-on-year. Strategic partnerships, including a cornerstone investment from iHeartMedia, underpin its international growth ambitions.

WCM Global Growth Limited has announced an increased fully franked dividend for Q1 FY2026, alongside a progressive dividend policy forecasting steady growth through September 2026.

WCM Global Growth Limited has announced a fully franked quarterly dividend of AUD 0.0209 per share, accompanied by a dividend reinvestment plan offering a 3% discount on new shares.

WCM Global Growth Limited reported a robust FY2025 with net profit soaring to $69.5 million and a 31% portfolio return, prompting increased dividends and a successful $76.7 million capital raise.

Life360 reported a robust Q3 2025 with 34% revenue growth and a significant jump in adjusted EBITDA, while advancing its advertising platform through the planned acquisition of Nativo and expanding into pet tracking services.

Associate Global Partners Limited (AGP) reported robust FY25 results, with funds under management climbing to $1.464 billion, driven by stellar investment returns and successful capital raisings. The firm is advancing its distribution reach and launching new products to sustain momentum.

Eden Innovations has successfully raised $4.35 million through a placement of shortfall securities, marking a key step in its financial reconstruction and global expansion plans.

Eden Innovations has raised $4.35 million through a placement of shortfall shares, marking a key step in its financial reconstruction and global commercialisation plans.

Dyno Nobel reports a robust FY25 with a 23% rise in EBIT excluding major one-offs, nearing completion of its Fertilisers business separation and setting ambitious new decarbonisation targets.

CSL Limited’s latest Capital Markets Day presentation highlights CSL Seqirus’s strategic positioning to capitalize on a recovering US influenza vaccine market and global growth opportunities.

PainChek has secured FDA De Novo clearance for its Adult App, opening immediate access to a $175 million AUD US long-term care market and advancing its Infant App commercialization targeting a $15 billion AUD global opportunity.